人福医药(600079.SH)：奥卡西平缓释片获得美国FDA暂定批准文号

Core Viewpoint - The company, Renfu Pharmaceutical, announced that its subsidiary, Wuhan Renfu Likang Pharmaceutical Co., Ltd., received a tentative approval number from the U.S. Food and Drug Administration (FDA) for Oxcarbazepine extended-release tablets, which are intended for the treatment of partial seizures in patients aged 6 and older [1]. Company Summary - Renfu Pharmaceutical holds a 75.33% stake in Wuhan Renfu Likang, with plans to acquire 100% equity based on a future repurchase agreement [1]. - The approved product, Oxcarbazepine extended-release tablets, targets a specific patient demographic, indicating a focused approach in the company's product development strategy [1].